In particular, FoxO3a seems to have a protective role in ER+ breast tumors [22,24,38]; therefore, it is reasonable to suppose that FoxO3a deregulation could favor the acquisition of a phenotype resistant to treatments targeting ER, such as tamoxifen. The gene discussed is ESR1; the disease is breast neoplasm.